TY  - JOUR 
AU  - Ordóñez García, José Luis
AU  - Amaral, Ana Teresa
AU  - Carcaboso, Angel M.
AU  - Herrero Martín, David
AU  - García Macias, María del Carmen
AU  - Sevillano, Vicky
AU  - Alonso López, Diego
AU  - Pascual-Pasto, Guillem
AU  - San Segundo, Laura
AU  - Vila-Ubach, Monica
AU  - Rodrígues, Telmo
AU  - Fraile Martín, Susana
AU  - Teodosio, Cristina
AU  - Mayo-Iscar, Agustín
AU  - Aracil, Miguel
AU  - Galmarini, Carlos María
AU  - Tirado, Oscar M.
AU  - Mora, Jaume
AU  - de Álava Casado, Enrique
PY  - 2015
UR  - http://hdl.handle.net/10366/154332
AB  - [EN] Recent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors (PARPinh) in combination with DNA damage repair (DDR) agents. Trabectedin is an antitumoral agent that...
LA  - eng
PB  - Impact Journals
KW  - Ewing sarcoma
KW  - PARP inhibitor
KW  - trabectedin
KW  - DNA damage
KW  - PDX models
KW  - Sarcoma, Ewing
KW  - DNA Damage
TI  - The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
DO  - 10.18632/ONCOTARGET.4303
T2  - Oncotarget
VL  - 6
M2  - 18875
ER  -